Literature DB >> 11331611

Induced myelination and demyelination in a conditional mouse model of Charcot-Marie-Tooth disease type 1A.

J Perea1, A Robertson, T Tolmachova, J Muddle, R H King, S Ponsford, P K Thomas, C Huxley.   

Abstract

Charcot-Marie-Tooth disease type 1A, a hereditary demyelinating neuropathy, is usually caused by overexpression of peripheral myelin protein 22 (PMP22) due to a genomic duplication. We have generated a transgenic mouse model in which mouse pmp22 overexpression can be regulated. In this mouse model, overexpression of pmp22 occurs specifically in Schwann cells of the peripheral nerve and is switched off when the mice are fed tetracycline. Overexpression of pmp22 throughout life (in the absence of tetracycline) causes demyelination. In contrast, myelination is nearly normal when pmp22 overexpression is switched off throughout life by feeding the mice tetracycline. When overexpression of pmp22 is switched off in adult mice, correction begins within 1 week and myelination is well advanced by 3 months (although the myelin sheaths are still thinner than normal), indicating that the Schwann cells are poised to start myelination. Upregulation of the gene in adult mice (which had previously had normal pmp22 expression) is followed by active demyelination within 1 week, which had plateaued by 8 weeks. This indicates that Schwann cells with mature myelin are sensitive to increased amounts of pmp22 such that they rapidly demyelinate. Thus, demyelination can largely be corrected within a few months, but the correction will be sensitive to subsequent upregulation of pmp22.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11331611     DOI: 10.1093/hmg/10.10.1007

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  27 in total

1.  Current Therapy for Charcot-Marie-Tooth Disease.

Authors:  Marina Grandis; Michael E Shy
Journal:  Curr Treat Options Neurol       Date:  2005-01       Impact factor: 3.598

2.  PMP22 antisense oligonucleotides reverse Charcot-Marie-Tooth disease type 1A features in rodent models.

Authors:  Hien Tran Zhao; Sagar Damle; Karli Ikeda-Lee; Steven Kuntz; Jian Li; Apoorva Mohan; Aneeza Kim; Gene Hung; Mark A Scheideler; Steven S Scherer; John Svaren; Eric E Swayze; Holly B Kordasiewicz
Journal:  J Clin Invest       Date:  2017-12-04       Impact factor: 14.808

Review 3.  Animal models of Charcot-Marie-Tooth disease type 1A.

Authors:  M W Sereda; K-A Nave
Journal:  Neuromolecular Med       Date:  2006       Impact factor: 3.843

Review 4.  Molecular genetics of autosomal-dominant demyelinating Charcot-Marie-Tooth disease.

Authors:  Henry Houlden; Mary M Reilly
Journal:  Neuromolecular Med       Date:  2006       Impact factor: 3.843

Review 5.  Role of immune cells in animal models for inherited peripheral neuropathies.

Authors:  Chi Wang Ip; Antje Kroner; Stefan Fischer; Martin Berghoff; Igor Kobsar; Mathias Mäurer; Rudolf Martini
Journal:  Neuromolecular Med       Date:  2006       Impact factor: 3.843

6.  Distal enhancers upstream of the Charcot-Marie-Tooth type 1A disease gene PMP22.

Authors:  Erin A Jones; Megan H Brewer; Rajini Srinivasan; Courtney Krueger; Guannan Sun; Kira N Charney; Sunduz Keles; Anthony Antonellis; John Svaren
Journal:  Hum Mol Genet       Date:  2011-12-15       Impact factor: 6.150

7.  Regulation of the PMP22 gene through an intronic enhancer.

Authors:  Erin A Jones; Camila Lopez-Anido; Rajini Srinivasan; Courtney Krueger; Li-Wei Chang; Rakesh Nagarajan; John Svaren
Journal:  J Neurosci       Date:  2011-03-16       Impact factor: 6.167

Review 8.  Understanding Schwann cell-neurone interactions: the key to Charcot-Marie-Tooth disease?

Authors:  Marcel Maier; Philipp Berger; Ueli Suter
Journal:  J Anat       Date:  2002-04       Impact factor: 2.610

Review 9.  Experimental therapeutics in hereditary neuropathies: the past, the present, and the future.

Authors:  David N Herrmann
Journal:  Neurotherapeutics       Date:  2008-10       Impact factor: 7.620

10.  Functional and comparative genomics analyses of pmp22 in medaka fish.

Authors:  Junji Itou; Mikita Suyama; Yukio Imamura; Tomonori Deguchi; Kazuhiro Fujimori; Shunsuke Yuba; Yutaka Kawarabayasi; Takashi Kawasaki
Journal:  BMC Neurosci       Date:  2009-06-17       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.